Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) saw unusually-strong trading volume on Monday . 1,129,714 shares changed hands during trading, an increase of 1,728% from the previous session’s volume of 61,805 shares.The stock last traded at $3.78 and had previously closed at $3.90.
Raia Drogasil Stock Down 2.1%
The business’s 50 day moving average is $3.57 and its two-hundred day moving average is $4.22.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. The business had revenue of $2.17 billion for the quarter, compared to the consensus estimate of $2.32 billion. As a group, equities analysts predict that Raia Drogasil S.A. will post 0.16 earnings per share for the current fiscal year.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
See Also
- Five stocks we like better than Raia Drogasil
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
